BMEA — Biomea Fusion Inc
NASDAQ · Healthcare · Biotechnology
$1.80
+$0.12 (+7.14%)
Biomea Fusion Inc (BMEA) is a biotechnology company listed on NASDAQ. It is led by Michael J. M. Hitchcock Ph.D., based in 1599 Industrial Road, San Carlos, CA, United States, 94070, with about 79 employees. Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral covalent small molecule drugs to treat patients with metabolic diseases in the United States. It's lead product candidate icovamenib, an orally bioavailable, potent, and covalent inhibitor of menin, a ubiquitously expressed scaffold protein that functions in histone modification and epigenetic gene regulation to impact multiple cellular processes including cell cycle control, apoptosis, and DNA damage repair. Biomea Fusion, Inc. was incorporated in 2017 and is headquartered in San Carlos, California.
Net income was -$66.4M. BMEA currently screens at market cap $94.7M.
Use this BMEA page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the BMEA quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the BMEA SEC filings page. Lician reads the product cache first so this HTML stays unique to Biomea Fusion Inc even when a live quote feed is slow.
About Biomea Fusion Inc
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral covalent small molecule drugs to treat patients with metabolic diseases in the United States. It's lead product candidate icovamenib, an orally bioavailable, potent, and covalent inhibitor of menin, a ubiquitously expressed scaffold protein that functions in histone modification and epigenetic gene regulation to impact multiple cellular processes including cell cycle control, apoptosis, and DNA damage repair. Biomea Fusion, Inc. was incorporated in 2017 and is headquartered in San Carlos, California.
BMEA Key Statistics
Market Cap
$94.66M
Volume
3.21M
Previous Close
$1.73
Day Range
$1.65 – $1.83
EPS
-$0.81
Revenue
$0.00
Net Income
-$138.43M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
79
BMEA Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 |
| Net Income | -$138.43M | -$117.25M |
| EPS (Diluted) | -$0.81 | -$0.98 |
Total Assets
$79.94M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$58.28M
Operating Cash Flow
-$119.89M
Free Cash Flow
$0.00
Biomea Fusion Inc Company Information
- Interim CEO & Director
- Michael J. M. Hitchcock Ph.D.
- Headquarters
- 1599 Industrial Road, San Carlos, CA, United States, 94070
- Website
- biomeafusion.com
- Phone
- 650 980 9099
- IPO / Founded
- 2021-04-16
- Sector
- Healthcare
- Industry
- Biotechnology